Simcor (simvastatin/niacin extended-release formulation) / AbbVie - LARVOL DELTA

An open source statistical web application for validation and analysis of virtual cohorts. (PubMed, Sci Rep) - "It is fully open, generic and menu driven and provides user guidance and help ( https://github.com/ecrin-github/SIMCor , https://zenodo.org/records/14718597 ).The tool has been developed according to specified user requirements and has been extensively tested and validated. Important next steps are to gain more experience with the tool in other domains and research environments and to extend its functionality."

Journal

Myocardial Protection Effect of Simvastatin Undergoing Cardiac Surgery (clinicaltrials.gov) - P=N/A | N=369 | Recruiting | Sponsor: Sun Yat-sen University | Trial completion date: Dec 2025 ➔ Dec 2026 | Trial primary completion date: Dec 2023 ➔ Dec 2024

Surgery • Trial completion date • Trial primary completion date • Cardiovascular • Heart Failure

Myocardial Protection Effect of Simvastatin Undergoing Cardiac Surgery (clinicaltrials.gov) - P=N/A | N=369 | Recruiting | Sponsor: Sun Yat-sen University | Trial completion date: Dec 2024 ➔ Dec 2025 | Trial primary completion date: Dec 2022 ➔ Dec 2023

Trial completion date • Trial primary completion date • Cardiovascular • Heart Failure

"SimCorp A/S – Share buyback program https://t.co/RKC23XgTCJ" (@CisionNews)

"SimCorp A/S – Share buyback program https://t.co/pXck7p7zgB" (@CisionNews)

"SimCorp A/S – Share buyback program https://t.co/iEuYJFCrlD" (@CisionNews)

"SimCorp A/S – Announcement of Managers’ Transactions https://t.co/P6k4hjMgHd" (@CisionNews)

"SimCorp A/S – Share buyback program https://t.co/L13ilUEx9g" (@CisionNews)

"SimCorp A/S - Major shareholder announcement https://t.co/zAl5Qf57Ea" (@CisionNews)

"SimCorp A/S – Share buyback program https://t.co/dCRKrIq3qI" (@CisionNews)

"SimCorp A/S – Share buyback program https://t.co/xveFZZN1ym" (@CisionNews)

"SimCorp A/S – Announcement of Managers’ Transactions https://t.co/ZQ4F1dBubN" (@CisionNews)

"SimCorp A/S – Share buyback program https://t.co/VV6hSuT7G6" (@CisionNews)

"SimCorp A/S – Share buyback program https://t.co/hCJdV1WxAZ" (@CisionNews)

"VALUE PERFORMANCE WELTWEIT - https://t.co/XrWVR0h3MY Nach #AEX25 (NL), #TA35 (IL) und #OMX30 (SE) hier nun die Unternehmen aus #OMXC20 (DK): @novonordisk, @Coloplast und @SimCorp sind die 3 TOP-Performer 2019 #IFRS #ValuePerformance #ShareholderValue" (@LSlatosch)

Translational Evidence of Dopamine-Related Alterations of Basal Ganglia and Thalamo-Cortical Neurocircuitry in Schizophrenia: A Full Clinic-To-Bench-To-Clinic Back-Translation (SIRS 2018) - "In addition, patients with schizophrenia showed a reduction in RSFC between the MGN and primaryauditory cortex, as well as between the LGN and primary visual cortex (P < 0.05, alphasimcorrected for whole-brain analysis).Conclusions These findings provide initial support for the existence of D2R-mediated alterations infunctional neuroanatomy, first observed in animal models of schizophrenia, in a clinical sample ofunmedicated patients. In addition to providing early evidence for potential mechanisms of psychoticphenomena, this work suggests that the use of non-invasive multiband RSFC is a promisingapproach to translating basic neuroscience findings in animal models back into a clinical setting.Altered circuitry was shown in the D2OE mice to underlie motivational deficits, and we propose thatthey may have a similar functional impact in patients."

Biosimilar • Schizophrenia

Gender differences in pharmacokinetics of a combination tablet of niacin extended-release/simvastatin in healthy Chinese volunteers (Eur J Drug Metab Pharmacokinet) - P=NA, N=36; "...the systemic exposure of simvastatin hydroxy acid and the total urine excretion of niacin were significantly higher for females compared with those for males, and the T max of niacin in plasma was significantly shorter for males than that for females."

Clinical data • Atherosclerosis • Dyslipidemia

Myocardial Protection Effect of Simvastatin Undergoing Cardiac Surgery (clinicaltrials.gov) - P=N/A; N=369; Recruiting; Sponsor: Sun Yat-sen University; Trial completion date: Dec 2021 ➔ Dec 2024; Trial primary completion date: Dec 2019 ➔ Dec 2022

Trial completion date • Trial primary completion date